Stifel keeps USD 260.00 target for Johnson & Johnson stock

Published on 10/13/2026 at 15:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock yields 2.00 percent on October 13, 2026. Price is EUR 226.05 on October 13, 2026, down 3.95 percent versus October 12 Xetra close.

Analyst target and market valuation

Stifel kept its USD 260.00 target and Hold rating for Johnson & Johnson on October 12, 2026.
Johnson & Johnson stock carried a 2.00 percent dividend yield on October 13, 2026.
Johnson & Johnson stock costs EUR 226.05 at Lang & Schwarz on October 13, 2026 at 3:35 p.m. CEST, minus 3.95 percent versus the Xetra close of October 12, 2026.
Johnson & Johnson had a USD 611.6 billion market capitalization and traded at 29.38 times earnings on October 13, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und Tabletten — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte symbolisiert Aktie von Johnson & Johnson, ISIN US4781601046, im Pharmasektor, Illustration mit AI erstellt.

Stifel maintained its Hold rating and USD 260.00 price target for Johnson & Johnson stock on October 12, 2026, according to Investing.com. The target stood 2.44 percent above the USD 253.81 primary-market price on October 13, 2026. Johnson & Johnson was trading at EUR 226.05 at Lang & Schwarz on October 13, 2026 at 3:35 p.m. CEST, minus 3.95 percent versus the Xetra close of October 12, 2026 at EUR 235.35.

Dividend yield stays at 2.00 percent

Johnson & Johnson carried a 2.00 percent dividend yield on October 13, 2026. The company profile identifies the business as a healthcare group operating through Innovative Medicine and MedTech, giving the yield a direct link to two established operating areas.

Price sits 9.70 percent below high

The primary-market price was USD 253.81 on October 13, 2026, while the 52-week range ran from USD 184.66 to USD 281.07. The current level was 9.70 percent below the 52-week high, leaving the stock above the midpoint of that range.

Johnson & Johnson's market capitalization stood at USD 611.6 billion on October 13, 2026. Trading volume was 1,106,523 shares against an average of 7,008,998, while the price-to-earnings ratio was 29.38.

Valuation at 29.38 times earnings

The valuation sits between two different healthcare reference points. Abbott Laboratories traded at 32.70 times earnings with a USD 176.1 billion market capitalization, while Merck traded at 115.90 times earnings with a USD 357.5 billion market capitalization on October 13, 2026.

Comparison with peers

Johnson & Johnson: minus 3.95 percent, P/E 29.38, market capitalization USD 611.6 billion.

Abbott Laboratories (NYSE, USD): minus 0.03 percent, P/E 32.70, market capitalization USD 176.1 billion.

Merck & Co. (NYSE, USD): minus 0.47 percent, P/E 115.90, market capitalization USD 357.5 billion.

Price and investor frame

For investors, the key contrast is a USD 260.00 target against a USD 253.81 primary-market price and an EUR 226.05 Lang & Schwarz quote. The target distance is modest, while the stock remains 9.70 percent below its 52-week high and carries a 2.00 percent dividend yield.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.